Sales grew for a fifth straight quarter at Herbalife
Herbalife reported Q3 2026 net sales of $1.35B, up 6.0% YoY, with adjusted EBITDA of $182.4M. Net income was $58.8M, and margins improved. The company revised full-year guidance, raising net sales expectations. Herbalife also announced a new $250M share repurchase program and leadership changes, including Scott Schaefer as CFO.
How this was made
The 30-second read
Why it matters
The key tradable elements are the quarter’s beat versus guidance, the 70 bps adjusted EBITDA margin expansion, and the full-year net sales guidance increase (while adjusted EBITDA guidance is maintained on a reported basis). The $250M share repurchase authorization can further support downside protection if the market focuses on cash generation.
Market read
A company-specific earnings and guidance update with a beat, margin expansion, and a full-year sales guidance raise, plus a new buyback program.
What to watch
The guidance includes constant-currency framing and FX translation assumptions; traders may scrutinize whether profitability gains persist if FX or regional trends worsen.
Background
Herbalife’s Q3 2026 release highlights ongoing transformation efforts, with leadership succession (interim CEO and new CFO) and capital return plans.
Ticker impact
Herbalife reported Q3 2026 net sales up 6.0% and adjusted EBITDA margin up 70 bps, and revised full-year net sales guidance higher.
Likely upward bias as traders price in higher full-year net sales guidance and improved profitability metrics.
The article discloses a quarter beat versus guidance, margin expansion, and a specific full-year net sales guidance increase, plus a $250M repurchase authorization.
Market effects
Supports sentiment for direct-selling and health-and-wellness consumer discretionary names by signaling demand resilience and margin improvement.
North America net sales growth continues for a second consecutive quarter, partially offsetting EMEA weakness.
Limited spillover beyond the company, but reinforces the broader theme of improving profitability alongside revenue growth.
Counterpoint
EMEA net sales declined year over year, so the raised full-year sales outlook may rely on continued North America strength and FX assumptions.
Key entities
- companyHerbalife Ltd.
Health and wellness company reporting Q3 2026 results, guidance updates, and a new share repurchase authorization.
- executiveJohn DeSimone
Interim CEO appointed effective Nov 1, 2026, commenting on sales growth and priorities.
- executiveScott Schaefer
CFO appointed effective Nov 1, 2026, commenting on beat versus guidance and interest expense savings.
